Lenacapavir Injection + Lenacapavir Tablet
Phase 3Recruiting 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
HIV Pre-exposure Prophylaxis
Conditions
HIV Pre-exposure Prophylaxis
Trial Timeline
Jul 22, 2025 → Sep 1, 2028
NCT ID
NCT07047716About Lenacapavir Injection + Lenacapavir Tablet
Lenacapavir Injection + Lenacapavir Tablet is a phase 3 stage product being developed by Gilead Sciences for HIV Pre-exposure Prophylaxis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07047716. Target conditions include HIV Pre-exposure Prophylaxis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07047716 | Phase 3 | Recruiting |
Competing Products
7 competing products in HIV Pre-exposure Prophylaxis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Oral Lenacapavir (LEN) + Subcutaneous (SC) Lenacapavir (LEN) + F/TAF + F/TDF + Placebo SC LEN + PTM Oral LEN + PTM F/TAF + PTM F/TDF | Gilead Sciences | Phase 3 | 76 |
| Lenacapavir Tablet + Lenacapavir Injection + Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) | Gilead Sciences | Phase 2 | 51 |
| Oral Lenacapavir (LEN) + F/TDF + Sub-cutaneous (SC) Lenacapavir (LEN) + Placebo SC LEN + PTM F/TDF + PTM Oral LEN + F/TAF (for US participants only) | Gilead Sciences | Phase 3 | 76 |
| Lenacapavir Injection + Lenacapavir Tablet + Emtricitabine/tenofovir disoproxil fumarate (F/TDF) | Gilead Sciences | Phase 2 | 51 |
| F/TAF + F/TDF + F/TAF Placebo + F/TDF Placebo | Gilead Sciences | Phase 3 | 76 |
| Lenacapavir Injection + Lenacapavir Tablet + Emtricitabine/tenofovir disoproxil fumarate (F/TDF) | Gilead Sciences | Phase 2 | 51 |
| Monoclonal antibody JST-010 + Placebo | Evotec | Phase 1 | 28 |